The Goldman Sachs Group Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $43.00

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target lowered by The Goldman Sachs Group from $48.00 to $43.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s price target indicates a potential upside of 264.84% from the company’s previous close.

DAWN has been the topic of several other research reports. Bank of America decreased their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Finally, Needham & Company LLC restated a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Price Performance

Shares of Day One Biopharmaceuticals stock traded down $0.26 during trading on Monday, hitting $11.79. 315,032 shares of the company’s stock traded hands, compared to its average volume of 1,061,818. The business has a 50-day simple moving average of $12.63 and a 200-day simple moving average of $13.64. Day One Biopharmaceuticals has a 1 year low of $11.13 and a 1 year high of $18.07. The stock has a market capitalization of $1.19 billion, a P/E ratio of -11.44 and a beta of -1.46.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total transaction of $399,300.00. Following the completion of the sale, the insider now directly owns 1,034,015 shares of the company’s stock, valued at $13,762,739.65. The trade was a 2.82 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Day One Biopharmaceuticals in the 4th quarter worth $525,000. Swiss National Bank grew its stake in Day One Biopharmaceuticals by 2.6% during the 4th quarter. Swiss National Bank now owns 117,800 shares of the company’s stock worth $1,493,000 after buying an additional 3,000 shares during the last quarter. Essex Investment Management Co. LLC grew its stake in Day One Biopharmaceuticals by 12.7% during the 4th quarter. Essex Investment Management Co. LLC now owns 207,574 shares of the company’s stock worth $2,630,000 after buying an additional 23,344 shares during the last quarter. Jackson Creek Investment Advisors LLC purchased a new position in Day One Biopharmaceuticals during the 4th quarter worth $1,313,000. Finally, E Fund Management Co. Ltd. purchased a new position in Day One Biopharmaceuticals during the 4th quarter worth $143,000. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.